Welcome to our dedicated page for Ashland news (Ticker: ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Ashland Inc. (NYSE: ASH) is a premier global specialty chemicals company that serves a wide range of consumer and industrial markets. With a workforce of nearly 7,000 passionate professionals, including renowned scientists, research chemists, talented engineers, and plant operators, Ashland thrives on developing practical, innovative, and elegant solutions to complex problems for customers in more than 100 countries.
Operating in four distinct segments—Life Sciences, Personal Care, Specialty Additives, and Intermediates—Ashland is a key supplier to pharmaceutical companies, manufacturers of personal care products, food and beverages, nutraceuticals, and supplements. The Life Sciences segment generates the highest revenue, reflecting the company’s strong focus on this area.
Recently, Ashland announced significant organizational changes within its finance, strategy, mergers and acquisitions (M&A), and portfolio teams. The company has also issued its first-quarter financial results for fiscal year 2024 and outlined its outlook for the second quarter and full year. Ashland's leadership positions in high-quality, consumer-focused markets such as pharmaceuticals, personal care, and architectural coatings underline its commitment to excellence.
Ashland continues to foster gender equity and empowerment by spotlighting inspirational female employees, particularly in recognition of International Women’s Day. The company recently increased its support for greenlight4girls, a global initiative to inspire girls in STEM fields.
In line with its strategic goals, Ashland has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. The transaction, expected to close in the third quarter of 2024, is subject to customary closing conditions.
For the latest updates and more detailed information, visit the official Ashland website and the Investor Relations section.
Ashland Inc. (NYSE: ASH) reported Q1 2023 sales of $525 million, reflecting a 3% increase year-over-year, primarily driven by strong demand for pharmaceutical ingredients. Net income decreased to $40 million, or $0.73 per diluted share, while income from continuing operations rose to $42 million, or $0.76 per diluted share. Adjusted EBITDA reached $108 million but faced pressures from foreign currency impacts and planned maintenance costs. Operating cash flow was negative $29 million, leading to ongoing free cash flow also remaining negative at $21 million. The company maintains its fiscal year 2023 sales guidance of $2.5 billion to $2.7 billion.
Ashland Inc. (NYSE: ASH) announced preliminary financial results for Q1 2023, reporting sales of approximately $525 million, a 3% year-over-year increase. Key factors influencing results included strong demand for pharmaceutical ingredients and resilient margins despite challenges in the Specialty Additives and Personal Care segments, primarily due to COVID-19 impacts and economic slowdowns in Europe. Expected income from continuing operations is around $42 million, or $0.76 per diluted share. Despite ongoing uncertainties, Ashland maintains its FY 2023 sales outlook of $2.5 billion to $2.7 billion and Adjusted EBITDA guidance of $600 million to $650 million.
The board of directors of Ashland has declared a quarterly cash dividend of $0.335 per share on its common stock. This dividend will be payable on March 15, 2023, to stockholders of record as of March 1, 2023.
As of December 31, 2022, Ashland had 54,271,587 shares of common stock outstanding. Ashland operates globally in additives and specialty ingredients, serving various markets including construction, energy, and pharmaceuticals, with a focus on environmental, social, and governance (ESG) practices.
Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.335 per share on its common stock. This dividend is scheduled for payment on December 15, 2022, to shareholders on record as of December 1, 2022. As of October 31, 2022, Ashland has 54,147,528 outstanding shares. Ashland is a global leader in additives and specialty ingredients, serving diverse markets including automotive, food and beverage, and pharmaceuticals, while emphasizing a commitment to environmental, social, and governance (ESG) principles.
Ashland Inc. (NYSE: ASH) reported Q4 fiscal 2022 results with sales of $631 million, a 7% increase year-over-year. Net income rose to $57 million, reflecting growth from $43 million in Q4 2021. Adjusted EBITDA was $147 million, slightly down from $149 million amid foreign currency challenges. The company expects 2023 sales between $2.5 billion and $2.7 billion, with adjusted EBITDA projected at $600 million to $650 million.
Ashland Inc. (NYSE: ASH) has received the Commitment to Life Award in the Human Rights category from Natura & Co for its Responsible Solvers™ program. This initiative promotes sustainable guar farming and aims to educate farmers in Rajasthan, India, utilizing STEM principles. Natura & Co emphasizes collaboration with suppliers to address environmental and social challenges. The Commitment to Life Awards evaluate suppliers' positive impact projects, showcasing Ashland's commitment to corporate social responsibility and its role in global sustainability efforts.
Ashland Inc. (NYSE: ASH) has achieved EcoVadis Gold, highlighting its commitment to environmental, social, and governance (ESG) practices. This recognition places Ashland in the top 5% of over 100,000 evaluated companies. The rating reflects the company's management systems across several non-financial areas, including labor, ethics, and sustainable procurement. This award follows the launch of Ashland's ESG Report and an enhanced ESG online presence, emphasizing transparency and the company's mission to foster a better world.
Ashland Inc. (NYSE: ASH) has announced that the FDA has accepted its Viatel™ bioresorbable mPEG-PDLLA pharmaceutical excipient into the Novel Excipient Review Pilot Program. This program allows for the review of novel excipients before their use in drug formulations, aiming to enhance public health. The excipient serves as a polymeric carrier for targeted drug delivery. Ashland's participation underscores its commitment to innovation in pharmaceutical ingredients, facilitating the development of complex drug molecules for improved therapeutic outcomes.
Ashland Inc. (NYSE: ASH) announced its plans to issue fourth-quarter earnings on November 7, 2022, at 5 p.m. ET, followed by a live webcast for analysts on November 8, 2022, at 9 a.m. ET. The webcast will feature remarks from CEO Guillermo Novo and CFO Kevin Willis. Participants can join via phone by registering through an online link. Supporting materials, including a slide presentation, will be available on the Investor Relations section of Ashland's website. The archived version of the webcast will be accessible for 12 months.
FAQ
What is the current stock price of Ashland (ASH)?
What is the market cap of Ashland (ASH)?
What does Ashland Inc. specialize in?
How many employees does Ashland Inc. have?
What are the main business segments of Ashland Inc.?
Who are some of Ashland Inc.'s key customers?
What recent organizational changes has Ashland Inc. announced?
How does Ashland Inc. support gender equity?
What strategic transaction did Ashland Inc. recently announce?
Where can I find Ashland Inc.'s financial updates?
What is Ashland Inc.'s ticker symbol and where is it listed?
What are some key markets served by Ashland Inc.?
